» Articles » PMID: 32282545

Enhancing Patient Adherence to Fecal Microbiota Transplantation Maintains the Long-term Clinical Effects in Ulcerative Colitis

Overview
Specialty Gastroenterology
Date 2020 Apr 14
PMID 32282545
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The way to improve the long-term efficacy of fecal microbiota transplantation (FMT) in ulcerative colitis (UC) remains unclear. This study mainly dedicated to the UC patients' satisfaction with FMT and the importance of patients' adherence to repeated FMT for long-term clinical outcomes.

Methods: Patients with UC who underwent FMT at our center from November 2012 to September 2018 were included. We assessed patient satisfaction with efficacy, safety, and reliability of FMT, as well as adherence to the repeated FMT.

Results: One hundred and seventy-six patients were included in the analysis. The median follow-up duration of the study was 25.5 (interquartile range 13.0-46.5) months. The clinical response rate at 1 week, 1 month, 3 months, and 6 months after FMT was 48.9%, 69.3%, 49.4%, and 32.7%, respectively. 3.4% (6/176) of patients underwent colectomy after FMT during our long-term follow-up. Partial Mayo score at 1-month post-FMT (P < 0.001) was an independent factor of patients' satisfaction. The laboratory preparation process was related to the incidence of adverse events (P < 0.05). 23.8% (29/122) of patients with a good adherence followed our recommendation to undergo the second course of FMT and achieved a longer clinical response compared with the patients with poor adherence (P < 0.001).

Conclusion: Patients' good adherence to repeated FMT is important to maintain long-term clinical benefits achieved from FMT in UC. Registration number: NCT01790061.

Citing Articles

Washed Microbiota Transplantation Improves the Sleep Quality in Patients with Inflammatory Bowel Disease.

Li Q, Liu Y, Zhang Z, Zhang S, Ding X, Zhang F Nat Sci Sleep. 2024; 16:1141-1152.

PMID: 39109266 PMC: 11302522. DOI: 10.2147/NSS.S460882.


Siderophore-harboring gut bacteria and fecal siderophore genes for predicting the responsiveness of fecal microbiota transplantation for active ulcerative colitis.

Yan J, Zhou G, Ren R, Zhang X, Zhang N, Wang Z J Transl Med. 2024; 22(1):589.

PMID: 38915068 PMC: 11194913. DOI: 10.1186/s12967-024-05419-w.


Current perspectives on fecal microbiota transplantation in inflammatory bowel disease.

Singh A, Midha V, Chauhan N, Sood A Indian J Gastroenterol. 2024; 43(1):129-144.

PMID: 38334893 DOI: 10.1007/s12664-023-01516-8.


Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease.

Zhang X, Ishikawa D, Ohkusa T, Fukuda S, Nagahara A Front Med (Lausanne). 2022; 9:1068567.

PMID: 36530877 PMC: 9755187. DOI: 10.3389/fmed.2022.1068567.


Fecal microbiota transplantation ameliorates experimental colitis gut microbiota and T-cell modulation.

Wen X, Wang H, Zhang M, Zhang M, Wang H, Yang X World J Gastroenterol. 2021; 27(21):2834-2849.

PMID: 34135557 PMC: 8173381. DOI: 10.3748/wjg.v27.i21.2834.